Merck Alzheimer’s Drug Fails in Trials

Feb 20, 2017

Merck has halted a trial of a promising Alzheimer’s drug, verubecestat, after it was determined that there was virtually no chance of it working.

The drugmaker announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1, in people with mild-to-moderate Alzheimer’s disease. Merck is stopping the study following the recommendation of the external Data Monitoring Committee, which assessed overall benefit/risk during a recent interim safety analysis, and determined that there was “virtually no chance of finding a positive clinical effect.”

Merck will continue a parallel study of verubecestat, looking into the drug’s effect in people at a much earlier stage of the disease, when the hope is that they have so little plaque that stopping it in its tracks will prevent further symptoms.

This news comes just weeks after Denmark-based Lundbeck abandoned its investigational Alzheimer's med.

Read the Merck press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments